Form 4/A for IONS IONIS PHARMACEUTICALS INC
Accepted 2024-09-04 00:00:00 ET · period of report 2024-02-02 · accession 0000874015-24-000200 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2024-09-04 | 2024-02-02 | IONS | Geary Richard S | EVP, Chief Development Off | S - Sale | $50.04 | -1,995 | 87.3K | -2% | -$99.8K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-02 | S | D | 1,995 | $50.04 | 87,300 | D | — | — | (F1) The original Form 4 filed on February 2, 2024 reported 1,961 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Mr. Geary. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.80 to $50.30 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. |